Click here to answer our weekly poll.
Dermatology Times Staff
Advertisement
Articles by Dermatology Times Staff
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.
In phase 3b data presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021 showed bimekizumab achieved superior levels of complete skin clearance compared to secukinumab for psoriasis.
A glimpse at what to expect from Dermatology Times this week.
Phase 3 trial of Otezla shows improved measures of disease severity in adults with mild to moderate plaque psoriasis regardless of their Body Surface Area affected by the disease.
Incyte's Phase 2 study evaluating ruxolitinib cream for vitiligo meets primary endpoint, shows improvement in body and facial repigmentation compared to placebo.
Tremfya phase 3 data shows skin clearance rates were maintained at 5 years with 55.5% of patients achieving an IGA score of 0% and 53% achieving PASI 100 response in VOYAGE 2 trial.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Topical retapamulin was effective in clearing impetigo lesions according to a presentation given at the recent Maui Derm conference.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Click here to answer our weekly poll.
A glimpse at what to expect from Dermatology Times this week.
Advertisement
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5